At 70, Singer Olivia Newton-John​ Using Cannabis To Treat Cancer.

September 24, 2018, 11:06 pm

≫ Next: Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.

≪ Previous: Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.

$

0

0

“At 70, Singer Olivia Newton-John​ Using Cannabis To Treat Cancer. Olivia Newton-John says she has been diagnosed with cancer for the third time in three decades. Newton-John says she’s “treating it naturally and doing really well.” The “Grease” star says she is taking cannabis oil, made from marijuana her husband John Easterling grows on their ranch in Santa Barbara. She said, “I believe I will win over it.”” https://sanfrancisco.cbslocal.com/2018/09/10/olivia-newton-john-cannabis-cancer/

“Grease star Olivia Newton-John is battling her breast cancer with cannabis. Grease star Olivia Newton-John is offering an update on her third battle with cancer and revealing how cannabis has become a key component in her treatment plan.”   http://www.digitalspy.com/showbiz/news/a865881/grease-olivia-newton-john-battling-breast-cancer-with-cannabis/

“Olivia Newton-John Says She’s Managing Breast Cancer with Cannabis. Newton-John explained that she uses cannabis oil to treat the pain and help her sleep, much of which her husband John Easterling (who runs Amazon Herb Company) grows for her. “I’m very lucky that I live in a state where it’s legal and that I have a husband who is a plant medicine man,” she said. “How lucky is that?” Newton-John also advocated for legalizing cannabis in her home country of Australia, adding, “My dream is that it will be available to all the cancer patients or people going through cancer or any kind of disease that causes pain.” Newton-John turns 70 on September 26.” http://exclaim.ca/music/article/olivia_newton-john_says_shes_managing_breast_cancer_with_cannabis

“Olivia Newton-John diagnosed with cancer for a third time but believes she ‘will win’ health battle with homegrown cannabis treatment. The Grease actress is using homegrown cannabis as part of her treatment to fight the disease. She drinks a cannabis mixture made by her herbalist husband to control the illness.” https://www.mirror.co.uk/3am/celebrity-news/olivia-newton-john-diagnosed-cancer-13220595

“Olivia Newton-John uses medical marijuana to treat cancer”  https://www.buzz.ie/celebs/olivia-newton-john-drinks-cannabis-extract-numb-pain-cancer-253796

“Olivia Newton-John reveals marijuana helping her beat cancer”   http://www.9news.com.au/national/2017/09/03/08/58/olivia-newton-john-backs-medicinal-cannabis

“Olivia Newton-John’s cancer battle is going well… Thanks to cannabis oil!”  https://closeronline.co.uk/celebrity/news/olivia-newton-john-daughter-chloe-lattanzi-cannabis-oil-cancer/ 

“Olivia Newton-John ‘Feeling Great’ as Source Denies ‘False’ Report Her Cancer Has Spread Further. “This is just false,” a source close to Newton-John tells PEOPLE. “She’s feeling and looking great. Everything that’s being reported about her diagnosis is the same news she released last year.” https://people.com/music/olivia-newton-john-denies-false-report-cancer-spread/

“Olivia Newton-John Reveals Secret Cancer Battle in 2013: ‘I Just Decided to Keep It to Myself.” Last year, Newton-John announced she’d been diagnosed with stage 4 breast cancer that had metastasized to her back, but the 69-year-old actress has been treating the illness with natural wellness therapies, including medicinal marijuana. A source close to Newton-John tells PEOPLE that she’s been feeling fine and healthy as of late.” https://people.com/music/olivia-newton-john-secret-cancer-battle-decided-keep-myself/

“Olivia Newton-John: It’s not just cancer sufferers needing help, carers do too. The mum-of-one discovered she had a tumour in the base of her spine last year. She had previously overcome breast cancer in 1992 after undergoing surgery and chemo, before secretly beating the disease again in 2013. Praising both husband John and her daughter Chloe, Olivia said: “Of course they’ve been a huge support, I think it’s hard for people on the outside – the care takers – because they have to be taken care of too sometimes, because it is hard for them.” John grows cannabis plants for Olivia, as she has chosen natural therapies such as cannabis oil to help ease her pain from the disease, instead of opioids and other drugs such as chemo this time round. He grows the plants in California where the couple live, as it is legal there.” https://startsat60.com/entertainment/tv-movies/olivia-newton-john-cancer-sufferers-carers-husband-john-help

“‘I use cannabis’: Olivia Newton-John talks cancer treatment” https://startsat60.com/health/i-use-cannabis-olivia-newton-john-opens-up-on-cancer-treatment

“Olivia Newton-John using cannabis oil as she battles cancer for the third time”  https://www.hellomagazine.com/healthandbeauty/health-and-fitness/2018091162192/olivia-newton-john-using-cannabis-oil-battles-cancer-third-time/

“Olivia Newton-John Is Using Cannabis Oil To Treat Her Cancer”  https://www.inverse.com/article/32780-cannabis-oil-cancer-treatment-cannabinoid-chemotherapy

“Olivia Newton John’s cannabis oil for cancer treatment” https://www.msn.com/en-nz/health/medical/olivia-newton-johns-cannabis-oil-for-cancer-treatment/ar-AAoTvE3

“‘I believe I will win’: Olivia Newton-John, 69, reveals the tragic cancer diagnosis she kept secret… as she fights the disease for a third time with the help of her husband” https://www.dailymail.co.uk/tvshowbiz/article-6148177/Olivia-Newton-John-69-reveals-tragic-cancer-diagnosis-kept-secret.html

“Olivia’s husband grows her medical marijuana”  https://au.be.yahoo.com/entertainment/celebrity/a/37038356/john-easterling-home-grows-olivia-newton-johns-medical-marijuana/

“Olivia Newton-John Admits to Using Home-Grown Medical Marijuana to Battle Cancer” http://popculture.com/2017/09/11/olivia-newton-john-medical-marijuana-breast-cancer/

“Olivia Newton-John Reveals She Was Unable to Walk After Cancer Relapse – and She’s Using Marijuana to Ease Pain. The 68-year-old said that the “hardest thing” has been her pain level, admitting that trying to do shows was “really agonizing.” Now, she’s been treating the pain with medical marijuana her husband John Easterling grows. “I’ll be fine,” said Newton-John.” https://people.com/music/olivia-newton-john-cancer-update-couldnt-walk-australian-60-minutes/

“Olivia Newton-John on Being a Cancer ‘Thriver’ and Using Weed to Cope with Her Relapse: It’s a ‘Healing Plant’. The actress also shared that she’s been treating the pain with medical marijuana her husband John Easterling grows. “People have this vision from the ’60s of people just sitting around and getting stoned,” she said. “It’s not about that. This plant is a healing plant. I think we need to change the vision of what it is because it helped me greatly and it helps with pain and inflammation.”” https://people.com/music/olivia-newton-john-cancer-relapse-weed/

“Olivia Newton-John reveals she is on medical cannabis for cancer” https://www.dailymail.co.uk/health/article-6171365/Olivia-Newton-John-reveals-medical-cannabis-breast-cancer.html

“‘It’s a magical miracle plant:’ Olivia Newton-John reveals husband John Easterling grows marijuana to aid her breast cancer battle” https://www.dailymail.co.uk/tvshowbiz/article-4869940/Olivia-Newton-John-benefits-medical-marijuana.html

“‘It’s really important and should be available’: Olivia Newton-John speaks about how ‘medical cannabis’ is helping her beat breast cancer” https://www.dailymail.co.uk/tvshowbiz/article-4846664/Olivia-Newton-John-talks-cannabis-use-time.html

“Olivia Newton-John voices her support for medical marijuana after revealing her husband grows the plant to aid her breast cancer battle” https://www.dailymail.co.uk/tvshowbiz/article-4891760/Olivia-Newton-John-voices-support-medical-marijuana.html

“‘Medical cannabis has helped me a lot’: Olivia Newton-John speaks candidly about the ‘healing remedies’ that have helped CURE her pain during her agonising cancer battle” https://www.dailymail.co.uk/tvshowbiz/article-5181401/Olivia-Newton-John-speaks-candidly-medical-cannabis.html

“Let’s Get Physical! Olivia Newton-John beams in green as she dazzles Melbourne crowds at charity walk to raise funds for her cancer research centre… after speaking candidly about her attempts to ‘win over’ the disease” https://www.dailymail.co.uk/tvshowbiz/article-6172857/Olivia-Newton-John-beams-green-dazzles-crowds-cancer-research-charity-walk.html

“Olivia Newton-John leads the biggest ever Wellness Walk and Research Run! With participant numbers up by over 50 per cent from last year, the beautiful grounds at La Trobe University were filled with a vibe of family, community, love and hope. Olivia Newton-John was an enthusiastic participant enjoying the sunshine, along with her husband John Easterling, her niece Tottie Goldsmith (herself an ONJ Centre Goodwill Champion) and other family members. She was grateful for the large crowd of people who were there to support her ONJ Centre.“It’s very moving actually, to see so many people turn out,” says Olivia. “It looks like there are more people than last year which is fantastic, people with their dogs and their children and their friends. It’s wonderful.”” https://www.onjcancercentre.org/news/article/2018/09/18/biggest-ever-wellness-walk-and-research-run

“Well over half a million dollars has been raised so far and while the event itself is over for this year, fundraising is still open until the 30 September. You can continue to support family and friends by donating to their page, or you can donate to Olivia’s page here: https://secure.artezpacific.com/registrant/FundraisingPage.aspx?registrationID=1213890&langPref=en-CA

“The Olivia Newton-John Cancer Wellness & Research Centre is at the frontier of cancer medicine, with over 200 ongoing clinical trials.” https://www.onjcancercentre.org/patients-family/clinical-trials

http://www.thctotalhealthcare.com/olivia-newton-john-champions-the-use-of-magical-miracle-medicinal-cannabis/

---

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.

October 3, 2018, 3:26 am

≫ Next: Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.

≪ Previous: At 70, Singer Olivia Newton-John​ Using Cannabis To Treat Cancer.

$

0

0

“Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet.

The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients.

RESULTS:

Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol.

CONCLUSION:

Pharmaceutical-grade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients.”

https://www.ncbi.nlm.nih.gov/pubmed/30275207

http://ar.iiarjournals.org/content/38/10/5831

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.

October 22, 2018, 9:06 am

≫ Next: Light-activatable cannabinoid prodrug for combined and target-specific photodynamic and cannabinoid therapy.

≪ Previous: Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.

$

0

0

“Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being.

Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs.

Cannabis users reported improvement in pain, general well-being, appetite, and nausea in 94, 87, 82, and 79% of cases, respectively. Importantly, 81.5% reported a high overall efficacy of cannabis in relieving symptoms. AEs related to cannabis use itself were mild.

Thus, medical cannabis use is prevalent in this HL cohort, and appears to be effective in ameliorating chemotherapy-related AEs.”

https://www.ncbi.nlm.nih.gov/pubmed/30343297

https://www.karger.com/Article/Abstract/493567

Light-activatable cannabinoid prodrug for combined and target-specific photodynamic and cannabinoid therapy.

October 23, 2018, 1:22 pm

≫ Next: Up-regulation of heme oxygenase-1 expression and inhibition of disease-associated features by cannabidiol in vascular smooth muscle cells.

≪ Previous: Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.

$

0

0

“Cannabinoids are emerging as promising antitumor drugs. However, complete tumor eradication solely by cannabinoid therapy remains challenging. In this study, we developed a far-red light activatable cannabinoid prodrug, which allows for tumor-specific and combinatory cannabinoid and photodynamic therapy. This prodrug consists of a phthalocyanine photosensitizer (PS), reactive oxygen species (ROS)-sensitive linker, and cannabinoid. It targets the type-2 cannabinoid receptor (CB2R) overexpressed in various types of cancers. Upon the 690-nm light irradiation, the PS produces cytotoxic ROS, which simultaneously cleaves the ROS-sensitive linker and subsequently releases the cannabinoid drug. We found that this unique multifunctional prodrug design offered dramatically improved therapeutic efficacy, and therefore provided a new strategy for targeted, controlled, and effective antitumor cannabinoid therapy.”

 https://www.ncbi.nlm.nih.gov/pubmed/30334393

https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics/volume-23/issue-10/108001/Light-activatable-cannabinoid-prodrug-for-combined-and-target-specific-photodynamic/10.1117/1.JBO.23.10.108001.short?SSO=1

Up-regulation of heme oxygenase-1 expression and inhibition of disease-associated features by cannabidiol in vascular smooth muscle cells.

October 25, 2018, 2:37 am

≫ Next: Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.

≪ Previous: Light-activatable cannabinoid prodrug for combined and target-specific photodynamic and cannabinoid therapy.

$

0

0

“Aberrant proliferation and migration of vascular smooth muscle cells (VSMC) have been closely linked to the development and progression of cardiovascular and cancer diseases.

The cytoprotective enzyme heme oxygenase-1 (HO-1) has been shown to mediate anti-proliferative and anti-migratory effects in VSMC. This study investigates the effect of cannabidiol (CBD), a non-psychoactive cannabinoid, on HO-1 expression and disease-associated functions of human umbilical artery smooth muscle cells (HUASMC).

HO-1 protein and mRNA were significantly increased by CBD in a time- and concentration-dependent manner. Although the expression of several cannabinoid-activated receptors (CB₁, CB₂, G protein-coupled receptor 55, transient receptor potential vanilloid 1) was verified in HUASMC, CBD was shown to induce HO-1 via none of these targets. Instead, the CBD-mediated increase in HO-1 protein was reversed by the glutathione precursor N-acetylcysteine, indicating the participation of reactive oxygen species (ROS) signaling; this was confirmed by flow cytometry-based ROS detection.

CBD-induced HO-1 expression was accompanied by inhibition of growth factor-mediated proliferation and migration of HUASMC. However, neither inhibition of HO-1 activity nor knockdown of HO-1 protein attenuated CBD-mediated anti-proliferative and anti-migratory effects. Indeed, inhibition or depletion of HO-1 resulted in induction of apoptosis and intensified CBD-mediated effects on proliferation and migration.

Collectively, this work provides the first indication of CBD-mediated enhancement of HO-1 in VSMC and potential protective effects against aberrant VSMC proliferation and migration. On the other hand, our data argue against a role of HO-1 in CBD-mediated inhibition of proliferation and migration while substantiating its anti-apoptotic role in oxidative stress-mediated cell fate.”

https://www.ncbi.nlm.nih.gov/pubmed/30349652

http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=26191&path[]=81658

Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.

October 28, 2018, 3:07 am

≫ Next: Oncology Clinicians and the Minnesota Medical Cannabis Program: A Survey on Medical Cannabis Practice Patterns, Barriers to Enrollment, and Educational Needs.

≪ Previous: Up-regulation of heme oxygenase-1 expression and inhibition of disease-associated features by cannabidiol in vascular smooth muscle cells.

$

0

0

 

“Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with poor prognosis and inadequate therapeutic outcome. This contribution reports the use of a cannabinoid derivative, WIN55,212-2 (WIN) on the growth of TNBC in a 4T1 syngeneic mouse model.

To reduce the well-known psychoactive side effects of cannabinoids, we prepared a nanomicellar formulation of WIN (SMA-WIN). In vivo biodistribution, in silico ADME predictions, anticancer activity, and psychoactive effect of WIN and SMA-WIN studies suggest that SMA-WIN formulation can reduce to greater extent tumor growth with milder psychoactive side effects when compared to free drug.

Finally, the effects of WIN and SMA-WIN in combination with doxorubicin (Doxo), an established chemotherapeutic agent for the treatment of TNBC, were investigated in vitro and in vivo. SMA-WIN in combination with Doxo showed therapeutic efficacy and was able to reduce the tumor volume of TNBC murine model drastically. Moreover, SMA-WIN, while favoring drug tumor accumulation, minimized the adverse psychoactive effects that have impeded the use of this agent in the clinic.

To our knowledge, this is the first report for the assessment of cannabinoid nanoparticles in vivo for the treatment of TNBC and its enhanced anticancer effect at low doses with Doxo. These findings suggest a new therapeutic strategy in the management of TNBC.”

https://www.ncbi.nlm.nih.gov/pubmed/30367922

https://www.sciencedirect.com/science/article/pii/S0168365918306114?via%3Dihub

Oncology Clinicians and the Minnesota Medical Cannabis Program: A Survey on Medical Cannabis Practice Patterns, Barriers to Enrollment, and Educational Needs.

November 15, 2018, 3:44 am

≫ Next: The endocannabinoid signaling system in cancer

≪ Previous: Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.

$

0

0

“Medical cannabis has been available in the State of Minnesota since July 2015 through the Minnesota Medical Cannabis Program (MMCP).

Objectives: Our study aimed to delineate oncology providers’ views on medical cannabis, identify barriers to patient enrollment, and assess clinicians’ interest in a clinical trial of medical cannabis in patients with stage IV cancer.

Results: Of the 529 eligible survey participants, 153 (29%) responded to our survey; 68 respondents were registered with the MMCP. Most identified themselves as a medical oncologist or medical oncology nurse practitioner/physician assistant (n=125, 82%), and most practiced in a community setting (n=102, 67%). Overall, 65% of respondents supported the use of medical cannabis. Perceived cost and inadequate research were the highest barriers to MMCP patient enrollment. The lowest barriers included lack of health group support for allowing certification of patients and risk of social stigma. Of all respondents, 36% lacked confidence in discussing the risks and benefits of medical cannabis, and 85% wanted more education.

Conclusions: Although support for cannabis use in the cancer setting is growing, significant barriers remain. This study illustrates a clear need to give clinicians both data and education to guide their discussions about the benefits, risks, and cost considerations of using medical cannabis for cancer-related symptoms.”

https://www.ncbi.nlm.nih.gov/pubmed/30426072

https://www.liebertpub.com/doi/10.1089/can.2018.0029

The endocannabinoid signaling system in cancer

November 17, 2018, 6:25 am

≫ Next: Naturally occurring compounds as pancreatic cancer therapeutics.

≪ Previous: Oncology Clinicians and the Minnesota Medical Cannabis Program: A Survey on Medical Cannabis Practice Patterns, Barriers to Enrollment, and Educational Needs.

$

0

0

“Changes in lipid metabolism are intimately related to cancer. Several classes of bioactive lipids play roles in the regulation of signaling pathways involved in neoplastic transformation and tumor growth and progression.

The endocannabinoid system, comprising lipid-derived endocannabinoids, their G-protein-coupled receptors (GPCRs), and the enzymes for their metabolism, is emerging as a promising therapeutic target in cancer.

This report highlights the main signaling pathways for the antitumor effects of the endocannabinoid system in cancer and its basic role in cancer pathogenesis, and discusses the alternative view of cannabinoid receptors as tumor promoters.

We focus on new players in the antitumor action of the endocannabinoid system and on emerging crosstalk among cannabinoid receptors and other membrane or nuclear receptors involved in cancer. We also discuss the enzyme MAGL, a key player in endocannabinoid metabolism that was recently recognized as a marker of tumor lipogenic phenotype.”

https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(13)00044-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614713000448%3Fshowall%3Dtrue

---

Naturally occurring compounds as pancreatic cancer therapeutics.

November 24, 2018, 3:46 am

≫ Next: miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/β-catenin signaling pathway in gastric carcinoma.

≪ Previous: The endocannabinoid signaling system in cancer

$

0

0

“Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.”

https://www.ncbi.nlm.nih.gov/pubmed/30459936

“The combination of natural products and standard of care chemotherapy has the potential to increase quality of life and lifespan in pancreatic cancer patients, even though a number of hurdles need to be overcome for routine clinical use.”  http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=26234&path[]=81769

“Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress–Related Genes. In conclusion, results presented here show that cannabinoids exert a remarkable antitumoral effect on pancreatic cancer cells in vitro and in vivo due to their ability to selectively induce apoptosis of these cells via activation of the p8-ATF-4-TRB3 proapoptotic pathway.”  http://cancerres.aacrjournals.org/content/66/13/6748

miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/β-catenin signaling pathway in gastric carcinoma.

December 1, 2018, 4:41 am

≫ Next: Cannabidiolic Acid-Mediated Interference with AP-1 Transcriptional Activity in MDA-MB-231 Breast Cancer Cells.

≪ Previous: Naturally occurring compounds as pancreatic cancer therapeutics.

$

0

0

“Gastric cancer (GC) is the most common malignancy and third leading cause of cancer mortality worldwide. The identification of a sensitive biomarker as well as effective therapeutic targets for the treatment of GC is of critical importance. microRNAs play significant roles in the development of cancer and may serve as promising therapeutic targets.

RESULTS:

In the present study, it was demonstrated that the cannabinoid receptor 1 (CB1R) was overexpressed, and miR-23b-3p and miR-130a-5p were downregulated, in GC cells. In addition, the results revealed that these effects are associated with malignant biological behaviors exhibited by GC cells. Furthermore, miR-23b-3p and miR-130a-5p may regulate CB1R expression via the Wnt/β-catenin signaling pathway.

CONCLUSION:

Our results suggested dysregulation of CB1R expression is closely related to the malignant biological behavior of gastric cancer cells. miRNA/CB1R-based therapy may represent a promising therapeutic strategy for the clinical treatment of GC patients.”

https://www.ncbi.nlm.nih.gov/pubmed/30498363

https://www.dovepress.com/mir-23b-3p-and-mir-130a-5p-affect-cell-growth-migration-and-invasion-b-peer-reviewed-article-OTT

Cannabidiolic Acid-Mediated Interference with AP-1 Transcriptional Activity in MDA-MB-231 Breast Cancer Cells.

December 1, 2018, 5:57 am

≫ Next: An Integrated Review of Cannabis and Cannabinoids in Adult Oncologic Pain Management.

≪ Previous: miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/β-catenin signaling pathway in gastric carcinoma.

$

0

0

 

“We reported that cannabidiolic acid (CBDA), a non-psychotropic constituent of fiber-type cannabis plants, down-regulates the mRNA expression of cyclooxygenase-2 (COX-2) in highly aggressive MDA-MB-231 human breast cancer cells. However, the molecular mechanism(s) underlying the CBDA suppression of COX-2 have not yet been elucidated in detail. In MDA-MB-231 cells, COX-2 expression is known to be tightly regulated by the transcriptional activity of activator protein-I (AP-1), which is composed of a heterodimer of c-Fos and c-Jun. AP-1-mediated transcriptional activity was inhibited by CBDA in a dose-dependent manner. The expression of c-fos was maintained at markedly lower levels (0.035) than basal c-jun expression levels (1.0), implicating c- fos as a limiting factor in the regulation of COX-2. Analyses indicated that CBDA abrogated the expression of c-fos mRNA without affecting c-jun. Collectively, these results suggest that CBDA abolishes the expression of COX-2 by interfering with AP-I activity in MDA-MB3-231 cells.”

https://www.ncbi.nlm.nih.gov/pubmed/30496661

An Integrated Review of Cannabis and Cannabinoids in Adult Oncologic Pain Management.

December 12, 2018, 2:53 am

≫ Next: Health-related quality of life across cancer cachexia stages.

≪ Previous: Cannabidiolic Acid-Mediated Interference with AP-1 Transcriptional Activity in MDA-MB-231 Breast Cancer Cells.

$

0

0

“The objective of this paper is to review the available literature regarding the use of cannabis and cannabinoids in adult oncologic pain management.

RESULTS:

The final number of articles included is nine articles. Of the nine studies reviewed, eight reviewed the effect of the cannabinoid THC on cancer pain, and one study reviewed the use of medicinally available whole plant cannabis. The following study types were included: multiple multi-center, randomized, placebo- controlled trials and two prospective observational survey studies.

RESULTS AND CONCLUSIONS:

Of the eight studies that reviewed the effect of the cannabinoid THC, five found THC to be more effective than placebo, one found THC to be more effective than placebo in American patients but ineffective in patients from other countries, and two found THC to be no more effective than placebo. The study that reviewed the effect of the whole plant cannabis found that there was a significant decrease in pain among those patients smoking cannabis.”

https://www.ncbi.nlm.nih.gov/pubmed/30527857

https://www.painmanagementnursing.org/article/S1524-9042(18)30209-1/fulltext

Health-related quality of life across cancer cachexia stages.

December 12, 2018, 3:11 am

≫ Next: Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study.

≪ Previous: An Integrated Review of Cannabis and Cannabinoids in Adult Oncologic Pain Management.

$

0

0

“Cancer cachexia (CC) is common in advanced cancer and is accompanied by negative effects on health-related quality of life (HRQOL).

However, methods to identify the impact of CC on HRQOL are limited.

Finally, the use of cannabinoids in treating appetite loss was examined,

54 patients underwent cannabinoid treatment for appetite loss within a community-based, physician-lead, medical cannabis clinic.

Edmonton Symptom Assessment System (ESAS) score for lack of appetite significantly improved between baseline and follow-up after cannabinoid treatment, with no significant difference in weight.

Improvement of HRQOL via appetite stimulation, may be achieved through a multidisciplinary approach, which includes cannabinoid therapy.”

 https://www.ncbi.nlm.nih.gov/pubmed/30525763

http://apm.amegroups.com/article/view/21116

Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study.

December 13, 2018, 3:41 am

≫ Next: Cannabinoid receptor expression in estrogen-dependent and estrogen-independent endometrial cancer.

≪ Previous: Health-related quality of life across cancer cachexia stages.

$

0

0

 

“In patients with cancer, the use of medical cannabis has increased significantly during the recent years. There is evidence that cannabis consumption may affect cognitive performance; however, this potential effect has not been investigated prospectively in patients with cancer to date.

We aimed to evaluate the effect of cannabis consumption on cognitive abilities as well as on symptom relief in patients with cancer during chemotherapy treatment.

RESULTS:

Improvement in executive functioning was demonstrated in the case group. In aspects of symptoms, improvement in fatigue, appetite and sleep disorder was demonstrated after cannabis consumption. Patients consuming cannabis did not differ from the control group in cognitive functioning over 3 months of use. No significant cognitive decline was observed in either group over time.

CONCLUSION:

These preliminary findings suggest that the short-term use of cannabis during chemotherapy treatment improved disease-related symptoms and did not affect cognitive skills in patients with cancer.”

 https://www.ncbi.nlm.nih.gov/pubmed/30540595

https://insights.ovid.com/crossref?an=00001813-201901000-00011

Cannabinoid receptor expression in estrogen-dependent and estrogen-independent endometrial cancer.

December 21, 2018, 3:51 am

≫ Next: Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology.

≪ Previous: Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study.

$

0

0

“The lack of good diagnostic/prognostic biomarkers and the often late presentation of endometrial cancer (EC) hinders the amelioration of the morbidity and mortality rates associated with this primarily estrogen-driven disease, a disease that is becoming more prevalent in the population.

Previous studies on the expression of the classical cannabinoid receptors, CB1 and CB2, suggest these could provide good diagnostic/prognostic biomarkers for EC but those observations have been contradictory. In this study, we sought to resolve the inconsistency of CB1 and CB2 expression levels in different EC studies.

To that end, we used qRT-PCR and immunohistochemistry (IHC) for CB1 and CB2 in endometrial biopsies from women with or without EC and found that transcript levels for both CB1 and CB2 were significantly decreased by 90 and 80%, respectively in EC. These observations were supported by histomorphometric studies where CB1 and CB2 staining intensity was decreased in all types of EC.

These data suggest that the loss of both types of CB receptors is potentially involved in the development of or progression of EC and that CB1 and CB2 receptor expression could serve as useful histological markers and therapeutic targets in the treatment of or prevention of EC.”

https://www.ncbi.nlm.nih.gov/pubmed/30569804

https://www.tandfonline.com/doi/abs/10.1080/10799893.2018.1531890?journalCode=irst20

---

Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology.

December 24, 2018, 3:19 am

≫ Next: Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells.

≪ Previous: Cannabinoid receptor expression in estrogen-dependent and estrogen-independent endometrial cancer.

$

0

0

“A flowering plant of variegated ingredients and psychoactive qualities, Cannabis has long been used for medicinal and recreational purposes.

Regulatory approvals have been gained across a broad range of palliative and therapeutic indications, and in some cases, included in standard treatment guidelines.

Areas covered: The use of Cannabis and cannabinoid-based-medicines in oncology is summarized in this article. Cannabinoids were classified according to natural and synthetic subtypes and their mechanisms of action expounded. The variability of available products is discussed in the clinical context and data regarding chemotherapy-induced nausea and vomiting, cancer-related pain, anorexia, insomnia and anxiety are presented.

Moreover, immunological and antineoplastic effects in preclinical and clinical trials are addressed. Concepts such as synergism or opposition with conventional treatment modalities, sequence of administration and dosage, molecular cross-talk and malignancy-cannabinoid congruence, are explored. Finally, side-effects, limitations in trial design and legislation barriers are related.

Expert opinion: Sufficient evidence supports use of Cannabis for palliative indications in oncology, however, patients should be carefully selected, guided and followed. Promising research suggests potent antineoplastic activity, but more data must be accrued before conclusions can be drawn.”

https://www.ncbi.nlm.nih.gov/pubmed/30572744

https://www.tandfonline.com/doi/abs/10.1080/13543784.2019.1561859?journalCode=ieid20

Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells.

January 2, 2019, 4:25 am

≫ Next: Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

≪ Previous: Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology.

$

0

0

 “Glioblastoma multiforme (GBM) is the most common and aggressive form of primary malignant brain tumor in adults, with poor prognosis. Extracellular vesicles (EVs) are key-mediators for cellular communication through transfer of proteins and genetic material. Cancers, such as GBM, use EV release for drug-efflux, pro-oncogenic signaling, invasion and immunosuppression; thus the modulation of EV release and cargo is of considerable clinical relevance. As EV-inhibitors have been shown to increase sensitivity of cancer cells to chemotherapy, and we recently showed that cannabidiol (CBD) is such an EV-modulator, we investigated whether CBD affects EV profile in GBM cells in the presence and absence of temozolomide (TMZ). Compared to controls, CBD-treated cells released EVs containing lower levels of pro-oncogenic miR21 and increased levels of anti-oncogenic miR126; these effects were greater than with TMZ alone. In addition, prohibitin (PHB), a multifunctional protein with mitochondrial protective properties and chemoresistant functions, was reduced in GBM cells following 1 h CBD treatment. This data suggests that CBD may, via modulation of EVs and PHB, act as an adjunct to enhance treatment efficacy in GBM, supporting evidence for efficacy of cannabinoids in GBM.”

https://www.ncbi.nlm.nih.gov/pubmed/30597288

“Cannabidiol (CBD) is a phytocannabinoid derived from Cannabis sativa and known for its anti-neoplastic and chemo-preventive activities. Known anti-cancerous effects of cannabinoids include inhibition of tumor proliferation, angiogenesis and induction of tumor cell death, while in GBM, additional effects on inhibition of invasiveness and stem-cell like properties have been observed. CBD has also been shown to selectively inhibit GBM proliferation and to induce death of cultured human GBM cells, as well as being effective against other cancers.  We have recently shown that CBD is a novel modulator of EV release in several cancer cell lines and we and other groups have shown that EV-modulators, including CBD, can significantly increase sensitivity of various cancer cells to chemotherapy. This supports emerging evidence that CBD has anti-cancer effects and indicates that CBD can be used to lower anti-chemotherapeutic responses to TMZ as well as modifying EV cargo to an anti-oncogenic signature in GBM.”

https://www.sciencedirect.com/science/article/pii/S1936523318305990?via%3Dihub

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

January 11, 2019, 3:19 am

≫ Next: Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells.

≪ Previous: Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells.

$

0

0

 “In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L., such as Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD), and their effects on inflammation and cancer-related pain.

The National Cancer Institute (NCI) currently recognizes medicinal C. sativa as an effective treatment for providing relief in a number of symptoms associated with cancer, including pain, loss of appetite, nausea and vomiting, and anxiety.

Several studies have described CBD as a multitarget molecule, acting as an adaptogen, and as a modulator, in different ways, depending on the type and location of disequilibrium both in the brain and in the body, mainly interacting with specific receptor proteins CB₁ and CB₂.

CBD is present in both medicinal and fibre-type C. sativa plants, but, unlike Δ⁹-THC, it is completely nonpsychoactive. Fibre-type C. sativa (hemp) differs from medicinal C. sativa, since it contains only few levels of Δ⁹-THC and high levels of CBD and related nonpsychoactive compounds.

In recent years, a number of preclinical researches have been focused on the role of CBD as an anticancer molecule, suggesting CBD (and CBD-like molecules present in the hemp extract) as a possible candidate for future clinical trials.

CBD has been found to possess antioxidant activity in many studies, thus suggesting a possible role in the prevention of both neurodegenerative and cardiovascular diseases. In animal models, CBD has been shown to inhibit the progression of several cancer types. Moreover, it has been found that coadministration of CBD and Δ⁹-THC, followed by radiation therapy, causes an increase of autophagy and apoptosis in cancer cells. In addition, CBD is able to inhibit cell proliferation and to increase apoptosis in different types of cancer models.

These activities seem to involve also alternative pathways, such as the interactions with TRPV and GRP55 receptor complexes. Moreover, the finding that the acidic precursor of CBD (cannabidiolic acid, CBDA) is able to inhibit the migration of breast cancer cells and to downregulate the proto-oncogene c-fos and the cyclooxygenase-2 (COX-2) highlights the possibility that CBDA might act on a common pathway of inflammation and cancer mechanisms, which might be responsible for its anticancer activity.

In the light of all these findings, in this review we explore the effects and the molecular mechanisms of CBD on inflammation and cancer processes, highlighting also the role of minor cannabinoids and noncannabinoids constituents of Δ⁹-THC deprived hemp.”

https://www.ncbi.nlm.nih.gov/pubmed/30627539

https://www.hindawi.com/journals/bmri/2018/1691428/

Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells.

January 21, 2019, 4:24 am

≫ Next: Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence.

≪ Previous: Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

$

0

0

“Cannabidiol (CBD), one of the compounds present in the marijuana plant, has anti-tumor properties, but its mechanism is not well known.

This study aimed to evaluate the apoptotic action of CBD in colorectal cancer (CRC) cells, and focused on its effects on the novel pro-apoptotic Noxa-reactive oxygen species (ROS) signaling pathway.

CBD experiments were performed using the CRC cell lines HCT116 and DLD-1. CBD induced apoptosis by regulating many pro- and anti-apoptotic proteins, of which Noxa showed significantly higher expression. To understand the relationship between Noxa and CBD-induced apoptosis, Noxa levels were downregulated using siRNA, and the expression of apoptosis markers decreased.

After ROS production was blocked, the level of Noxa also decreased, suggesting that ROS is involved in the regulation of Noxa, which along with ROS is a well-known pro-apoptotic signaling agents. As a result, CBD induced apoptosis in a Noxa-and-ROS-dependent manner.

Taken together, the results obtained in this study re-demonstrated the effects of CBD treatment in vivo, thus confirming its role as a novel, reliable anticancer drug.”

https://www.ncbi.nlm.nih.gov/pubmed/30660647

“Our results using cells, mice, and patient-derived cells strongly suggest, for the first time, that that CBD can cause Noxa-induced cell death. These results suggest that that CBD has important implications for the potential treatment of human CRC.”

 https://www.sciencedirect.com/science/article/pii/S0304383519300230?via%3Dihub

Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence.

January 27, 2019, 6:38 am

≫ Next: Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model.

≪ Previous: Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells.

$

0

0

 “There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was confirmed in neuropathic pain management and combination with opioids. A relatively favorable adverse effects profile, including no depressive effect on the respiratory system, may make cannabis complement a rather narrow armamentarium that is in the disposition of a palliative care professional.”

https://www.ncbi.nlm.nih.gov/pubmed/30678303

https://www.mdpi.com/2072-6694/11/2/129